1. Home
  2. ABAT vs PRTA Comparison

ABAT vs PRTA Comparison

Compare ABAT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Battery Technology Company

ABAT

American Battery Technology Company

HOLD

Current Price

$2.72

Market Cap

517.0M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.02

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABAT
PRTA
Founded
2011
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
517.0M
526.7M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
ABAT
PRTA
Price
$2.72
$10.02
Analyst Decision
Strong Buy
Buy
Analyst Count
1
9
Target Price
$6.00
$19.00
AVG Volume (30 Days)
8.0M
531.3K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
43.14
N/A
EPS
N/A
0.60
Revenue
N/A
$814,000.00
Revenue This Year
$145.40
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$15.45
Revenue Growth
N/A
N/A
52 Week Low
$1.48
$5.96
52 Week High
$11.49
$11.80

Technical Indicators

Market Signals
Indicator
ABAT
PRTA
Relative Strength Index (RSI) 36.65 57.23
Support Level $2.63 $8.20
Resistance Level $3.67 $10.34
Average True Range (ATR) 0.33 0.54
MACD -0.09 0.18
Stochastic Oscillator 2.81 90.78

Price Performance

Historical Comparison
ABAT
PRTA

About ABAT American Battery Technology Company

American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: